EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Neonatal SARS‐CoV‐2 mRNA Vaccination Efficacy Is Influenced by Maternal Antibodies

Amy Schumer iD, Elizabeth A Bonney, Ethan Harby, Devdoot Majumdar

American Journal of Reproductive Immunology · 2024-10 · 92 (4)

DOI: 10.1111/aji.70001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Reproductive Immunology, online erschienen am 22.10.2024. Verfasst von Amy Schumer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Vermont Medical Center, Burlington, Vermont, USA. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, Antibodies, Viral, SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCRR NIH HHS, NIGMS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Problem Vaccination in pregnancy guards against infection. Maternal antibodies, however, can inhibit antibody production in neonates. We sought to determine the effects of maternal vaccination on neonatal immune response to a SARS‐CoV‐2 mRNA vaccine. Method of Study We hypothesized that mRNA‐lipid nanoparticles (LNP) vaccination allows for a de novo neonatal antibody response even in the presence of vertically transmitted maternal antibodies. Female mice were vaccinated with SARS‐CoV‐2 spike receptor binding domain (RBD) mRNA‐LNPs. Mice were then bred, and 21‐day‐old pups were inoculated with the same mRNA‐LNPs. Spike‐specific IgG ELISAs were performed using mouse serum. A SARS‐CoV‐2 spike protein peptide library to perform peptide ELISAs characterized high affinity binding domains within the spike protein. Results were analyzed with one‐way ANOVAs with Tukey's multiple comparisons tests.

Results

Compared to pups of unvaccinated dams, there were high levels of spike‐specific IgG detected in the pups of vaccinated dams at 3 weeks of life ( p < 0.0001). After neonatal vaccination, pups of unvaccinated dams had higher spike‐specific serum IgG than pups of vaccinated dams at 12 weeks of life ( p < 0.001). Antibody specificity to peptide moieties within spike RBD were similar when comparing a vaccinated dam to her pup at Week 3 of life, with different binding affinities observed in the pups by Week 15 of life.

Conclusions

Pre‐existing maternal antibodies may partially blunt the initial neonatal antibody response to mRNA‐LNPs vaccination. This vaccine strategy, however, does not prohibit the subsequent development of a broad range of RBD antibody specificities that may be protective.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spike Glycoprotein, CoronavirusAntibodies, ViralSARS-CoV-2COVID-19COVID-19 VaccinesAnimals, NewbornImmunoglobulin GVaccinationFemaleAnimalsMicePregnancyImmunity, Maternally-AcquiredNanoparticlesHumansRNA, MessengermRNA VaccinesLiposomes

Stichwörter der Autor:innen

SARS‐CoV‐2mRNA vaccinationmaternal antibodiesneonatal immunitypregnancyvertical transmission

Substanzen

Spike Glycoprotein, CoronavirusAntibodies, ViralCOVID-19 VaccinesImmunoglobulin Gspike protein, SARS-CoV-2Lipid NanoparticlesRNA, MessengermRNA VaccinesLiposomes

Autor:innen und Institutionen

  • Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Vermont Medical Center, Burlington, Vermont, USA.
  • Biological Sciences, University of Vermont, Burlington, Vermont, USA.
  • Department of Surgery, University of Vermont Medical Center, Burlington, Vermont, USA.
  • Department of Electrical and Biomedical Engineering, University of Vermont Medical Center, Burlington, Vermont, USA.
  • UVM Cancer Center, University of Vermont Medical Center, Burlington, Vermont, USA.

ORCID-Profile: Amy Schumer

Förderung

  • NCRR NIH HHS
  • NIGMS NIH HHS
  • NIH HHS
  • National Institutes of Health
  • National Institute of General Medical Sciences

Zitieren

APA

Schumer, A., Bonney, E. A., Harby, E., & Majumdar, D. (2024). Neonatal SARS‐CoV‐2 mRNA Vaccination Efficacy Is Influenced by Maternal Antibodies. American Journal of Reproductive Immunology, 92(4). https://doi.org/10.1111/aji.70001

Vancouver

Schumer A, Bonney EA, Harby E, Majumdar D. Neonatal SARS‐CoV‐2 mRNA Vaccination Efficacy Is Influenced by Maternal Antibodies. American Journal of Reproductive Immunology. 2024;92(4). doi:10.1111/aji.70001

BibTeX
@article{Schumer2024,
  author = {Schumer, Amy and Bonney, Elizabeth A and Harby, Ethan and Majumdar, Devdoot},
  title = {Neonatal SARS‐CoV‐2 mRNA Vaccination Efficacy Is Influenced by Maternal Antibodies},
  journal = {American Journal of Reproductive Immunology},
  year = {2024},
  volume = {92},
  number = {4},
  doi = {10.1111/aji.70001}
}
Kostenlos starten →